Physician profile
Marc I Epstein
NPI 1902929318
$13,356.62
in general payments reported to CMS, 2019-2025
35 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,073 · 2020: $835 · 2021: $1,925 · 2022: $2,054 · 2023: $2,028 · 2024: $2,697 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,912 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $340 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,912.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $340.25 |
| Education | $217.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,619.10 | 2019-2025 | |
| Janssen Biotech, INC. | $2,612.70 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,109.19 | 2019-2023 | Siliq |
| Pfizer INC. | $774.12 | 2019-2025 | |
| Genentech USA, INC. | $693.29 | 2019-2024 | Erivedge |
| Sun Pharmaceutical Industries INC. | $649.14 | 2020-2025 | Odomzo, Blu-U, Ilumya |
| Regeneron Healthcare Solutions, INC. | $633.98 | 2019-2025 | Libtayo |
| Incyte Corporation | $579.90 | 2021-2024 | Opzelura |
| Dermavant Sciences, INC. | $461.75 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $435.56 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $389.20 | 2019-2025 | Olumiant, Taltz |
| E.R. Squibb & Sons, L.L.C. | $330.80 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $308.09 | 2024-2025 | Anzupgo, Adbry |
| Genzyme Corporation | $308.02 | 2020-2025 | |
| Celgene Corporation | $161.28 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $146.89 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $146.12 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $137.53 | 2025 | Acthar |
| Merz North America, INC. | $116.84 | 2019-2021 | |
| Ucb, INC. | $114.39 | 2021-2025 | Bimzelx |
| Musculoskeletal Transplant Foundation INC. | $107.35 | 2021 | |
| Almirall LLC | $81.15 | 2019-2025 | Klisyri |
| Helsinn Therapeutics (U.S.), INC. | $78.10 | 2020-2023 | Valchlor |
| Dusa Pharmaceuticals, INC. | $61.91 | 2019 | |
| Organon LLC | $50.49 | 2025 | Vtama |
| Sirtex Medical INC | $49.00 | 2020 | |
| Revance Therapeutics, INC. | $48.87 | 2025 | Daxxify |
| Epi Health, LLC | $33.45 | 2019-2022 | |
| Biocon Biologics INC | $22.05 | 2025 | Hulio |
| Biofrontera INC. | $21.10 | 2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Encore Dermatology INC. | $16.11 | 2020 | |
| Oxford Immunotec USA INC | $15.49 | 2021 | |
| Mayne Pharma Commercial LLC | $15.41 | 2021 | |
| Arcutis Biotherapeutics, INC. | $15.12 | 2023 | |
| Kyowa Kirin, INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.